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Background: Bioimpedance is an electrical property of living tissue that has been shown 
to be a safe technique when used in a number of biomedical applications. The aim of this 
research was to assess the utility of bioimpedance measurement as a rapid, cost-effective, and 
noninvasive adjunct to digital rectal examination and PSA in differentiating tumor from normal 
prostatic tissue.
Methods: Three hundred men were examined for signs and symptoms of prostate disorders. 
147 patients with a digital rectal examination indicating a positive result underwent a prostate-
specific antigen (PSA) test. A biopsy was advised for 103 of the men, of whom 50 completed the 
study. Before undergoing biopsy, an examination with the EIS (electro interstitial scan) system 
using bioimpedance and chronoamperometry was performed. In reference to the biopsy results 
(negative or positive), a statistical analysis of the EIS data and PSA was conducted using receiver 
operating characteristic curves to determine the specificity and sensitivity of each test.
Results: The PSA test had a sensitivity of 73.9% and specificity of 51.9% using a cutoff value .4 
and a sensitivity of 52.2% and specificity of 81.5% using a cutoff value $5.7 and P = 0.03. The 
delta of the electrical conductivity (DE) of the left foot-right foot pathway had a sensitivity of 
62.5% and specificity of 85.2%, with a cutoff value #−5 and P = 0.0001. Algorithms comprising 
the delta of electrical conductivity and PSA showed a sensitivity of 91.5% and a specificity of 
59.3%, with a cutoff value #−10.52 and P = 0.0003.
Conclusion: The EIS system had a very good specificity of 85.2%. However, the sensitivity 
of 62.5% would be a problem. Using a PSA reference .4.1 ng/mL, the adjunctive use of 
bioimpedance and chronoamperometry provided by EIS technology could raise the sensitivity 
from 73.9% to 91.5% and the specificity from 51.9% to 59.3% in prostate cancer screening.
Keywords: prostate cancer screening, bioimpedance, delta of conductivity, electro interstitial 
scan system
Introduction
In the US, prostate cancer is the most commonly diagnosed malignancy and the second 
leading cause of mortality from cancer in men.1 In 1997, there were at least 209,900 
new cases of prostate cancer diagnosed and more than 41,800 deaths from prostate 
cancer.2 At present, a transrectal ultrasound with prostatic biopsy is recommended in 
men with an abnormal digital rectal examination and/or an elevated prostate-specific 
antigen (PSA) level, and who are potential candidates for therapy.
According to the US Bureau of the Census in 1998, there were an estimated 
30 million men in the US over the age of 50 years.3 A subset of this population represents 
those men who should undergo screening according to recommendations made by the 
American Urological Association.4 In a study by Arcangeli et al,6 8%–15% of men Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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screened were estimated to have an abnormal PSA test (ie, 
serum PSA $ 4.1 ng/mL by monoclonal assay) or had an 
abnormal digital rectal examination, half of whom had no 
identifiable pathology on biopsy.5 A further study has shown 
that about 66% of men with abnormally elevated PSA levels 
go on to have a negative biopsy,6 and another showed that 
19%–32% of men who agreed to undergo biopsy were found 
to have prostate cancer.5 An indicator/marker adjunctive to the 
digital rectal examination and PSA would help the clinician 
in the decision to perform a biopsy.
Bioimpedance is an electrical property of living tissue 
that has been shown to be a safe technique when used 
in a number of biomedical applications, including for 
quantification of brain edema in neurosurgery7 and for 
differentiating between cancer and pneumonia on discovery 
of a pulmonary mass.8 Electric current is normally limited in 
living tissue by highly insulating cell membranes. However, 
the abnormal architecture in cancerous tissue may impede 
current differently and allow detection of differences between 
normal and abnormal or malignant prostate tissue.9
The aim of this research was to assess the utility of 
bioimpedance measurement as a rapid, cost-effective, and 
noninvasive adjunct to digital rectal examination and PSA 
in differentiating tumor from normal prostatic tissue.
One explanation as to why bioimpedance increases in 
cancer tissue is the distorted architecture of the gland, which 
prevents flow of current. Histologically, the prostate can be 
thought of as being composed of multiple layers of hollow 
glands (ie, tubes). Solid or gross tumor tissue is also   composed 
of a histological array of tubes. The lumina in normal prostate 
tissue are open and have relatively large diameters, providing 
little resistance to flow. In contrast, as resistance increases, 
the current flow will decrease. Accordingly, in cancerous 
prostate tissue, the normal architecture of the lumina becomes 
distorted. The lumina of the tubes become much smaller, the 
walls of the glands become crowded, and the flow of current 
is impeded.9
The second explanation could be the electrochemical 
reaction in the anode related to the Chloride ions migration. 
The electrochemical reaction provides 4 H+ and is therefore 
an acid environment.
The pronounced elevations in prostatic tissue palmitoleic 
acid in cancer patients highlight a possible role of this fatty 
acid in neoplastic processes.10
We compared the results of PSA testing and biopsy 
with the results of EIS measurement to determine if the EIS 
system could be used as an adjunct to screening for prostate 
cancer.
Materials and methods
This study was approved by the regional ethic committee 
(Pesquisa CONEP, 125/10), and adhered to the ethical 
  principles of the Declaration of Helsinki. Each patient 
signed an informed consent form, and confidentiality was 
maintained for all participants.
subjects
Patients attending consultations for signs and/or symptoms of 
a prostatic disorder and not receiving any prostate treatment, 
as well as responders to an advertisement were considered 
for enrolment into this study. Inclusion criteria were a high 
PSA test result (.4 ng/mL) and/or a positive digital rectal 
examination with a clinical recommendation of prostate 
biopsy. Patients were excluded if they had previously 
undergone prostate-related chemotherapy or surgery, were 
currently receiving treatment for a prostatic disorder, had 
a neurological disorder precluding the ability to sign a 
consent form, if in the opinion of the investigator they were 
clinically unsuitable candidates for the trial, and/or had any 
contraindications to use of the EIS system. Use of the EIS 
system is contraindicated in the presence of an external 
defibrillator, skin lesions likely to come into contact with 
the electrodes, excessive perspiration, sinusitis (particularly 
frontal), cardiac pacemaker, electronic life support, any 
implanted electronic device, inability to remain still for 
three minutes, metallic pins or prostheses in digits or joints, 
pregnancy from the third trimester onwards, and absence 
of a limb.
Three hundred patients of mean age 65 (range 49–90) 
years were included in the study, and were examined 
in the office for signs and symptoms. A digital rectal 
  examination was performed, and if indicated, the patients 
were sent to the laboratory for a PSA test. If the attending 
clinician subsequently decided that a patient should have a 
  prostate biopsy, the patient underwent an EIS bioimpedance 
  measurement prior to the biopsy.
Measurement of bioimpedance
The parameter used by the EIS is the delta of the electrical 
resistance values between the pathway value for left foot to 
right foot (anode to cathode) minus the pathway value for 
right foot to left foot (cathode to anode), expressed in numeric 
form on a scale from 0 to 100.
The EIS is a programmable electromedical system 
  comprising a USB plug and hardware including an interface 
box, disposable electrodes, reusable plates, and reusable 
cables, with software installed on a computer. The system Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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uses bioimpedance in bipolar mode with direct current, 
and measures the electrical conductivity of 11 pathways of 
the body, each recorded twice from anode to cathode and 
then from cathode to anode. The pathways are measured 
between four large tactile reusable electrodes (.270 cm2) 
placed on the palms of the hands and soles of the feet, and 
smaller disposable electrodes (15 cm2) placed on the left 
and right forehead. Electrode polarization does not affect 
the bioimpedance measurement,11 and the transmission of 
the current from the electrode to the hardware is performed 
by chronoamperometry.12
eis and electrical conductivity/chronoamperometry
With direct current, the plasma membrane acts as an insulator 
and the current is not able to penetrate the cell, so most of the 
current flows around the cell and therefore in the interstitial 
fluid.13 Analysis of the direct current at the cathode and anode 
in electrolytic solution is performed at both the anode and 
the cathode.13
Analysis at the cathode
The electrochemical reaction at the cathode is:
2H2O + 2e = H2 (gas) + 2 OH-(base)
Analysis at the anode
The electrochemical reaction for water at the anode is:
2H2O = O2 (gas) + 4H+ + 4e-(acid)
Parameters analyzed
Analysis of the specificity and sensitivity of the data was done 
in accordance with the biopsy results. Receiver-operating 
characteristic curves were constructed for the PSA value and 
tissue diagnosis and for the EIS data and tissue diagnosis, 
and algorithms were constructed for the PSA-EIS data and 
tissue diagnosis. Raw analysis of the EIS data as an adjunct 
to the PSA value was also undertaken.
statistical analysis
Statistical analysis of the results was performed using 
MedCalc software. The number of patients needed for 
the study was calculated to be 50 on the basis of α = 5%, 
at 80% power = F (∆, N, variability DS), taking into 
account the judgment criteria ∆ at approximately 50 DS 
(5% error).
A P value of ,0.005 was accepted as being statistically 
significant.
Results
The results of this investigation showed that PSA had a 
sensitivity of 73.9% and a specificity of 51.9% for the 
  detection of prostate cancer using a cutoff value .4 
 ( Figure 1) and a sensitivity of 52.2% and specificity of 81.5% 
using a cutoff value $5.7 (P = 0.03) (Figure 2).
The delta for the electrical conductivity (DE) of the 
pathway from left foot to right foot had a sensitivity of 
62.5% and a specificity of 85.2% using a cutoff value #−5 
(P = 0.0001) (Figure 3).
The algorithms All (PSA Value multiplied by the 
delta value for the electrical conductivity) incorporating 
the delta of electrical conductivity and PSA value had a 
  sensitivity of 91.5% and a specificity of 59.3% using a cutoff 
value #−10.52 (P = 0.0003) (Figure 4).
Raw analysis of the EIS data as an adjunct to the PSA 
value (Tables 1 and 2).
Discussion
Although strategies for primary prevention of prostate cancer 
are being tested, to date none are known to be effective. The 
most common strategy for reducing the burden of prostate 
cancer is screening, but this remains controversial. Urologists 
are often faced with the dilemma of elevated PSA in young 
patients. This is a difficult situation, because these patients 
often do not want to undergo a prostate biopsy and fear a 
diagnosis of prostate cancer due to the potential side effects 
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Figure  1  Receiver-operating  characteristic  curve:  PsA  cutoff  value  .4  ng/mL 
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of treatment, including the possibility of urinary incontinence 
and erectile dysfunction.
Criteria for a clinically useful screening test are:
•	 The disease must constitute a serious public health 
problem
•	 The disease must be able to be diagnosed during an 
asymptomatic, localized phase
•	 The screening test must have an appropriate sensitivity, 
specificity, and predictive value
•	 The potential for cure must be greater in patients detected 
by screening
•	 Improved outcomes related to screening must be shown 
and, after these criteria are satisfied, the cost-effectiveness 
of the screening program must also be justified.14
The importance of prostate cancer as a public health 
problem and the fact that it can be diagnosed during an 
asymptomatic, localized stage easily satisfy using PSA and 
digital rectal examination as screening tools for the first two 
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Figure 2 Receiver-operating characteristic curve and data analysis: PsA cutoff value .5.7 ng/mL comparing positive biopsy group versus negative biopsy group.
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Figure 3 Receiver-operating characteristic curve and data analysis: Delta electrical conductivity (De) cutoff value #−5 comparing positive biopsy group versus negative 
biopsy group.
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Figure 4 Receiver-operating characteristic curve and data analysis: Test All cutoff value #−10.52 comparing positive biopsy group versus negative biopsy group.
*ALL Delta of the electrical conductivity value multiplied by the PsA value.
of the above-listed criteria, but there are no clear answers 
for the rest.
An autopsy study in Detroit men found previously 
undiagnosed prostate cancer in 30% of men in the age 
range 20–40 years, and in more than one half of men older 
than 50 years. The prevalence of these unsuspected prostate 
cancers is consistently estimated to be about 33%.15 These 
high rates of unsuspected prostate cancers are in sharp 
contrast with the 3.64% estimated lifetime risk of dying 
from prostate cancer, as well as the 1.8% detection rate 
Table 1 Analysis of the positive patients group
Patient  
code
Age Positivie test = 1 
Negative test = 0
Delta  
DE
PSA ALL 
[DE-PSA]  
,-10.52
Delta  
DE #-0.5
PSA $-4 ALL  
[DE - PSA]  
#10.52
Current  
treatment
1Zh05 57 1 −6 200.2 −1201.2 X X X no treatment
1ZM13 90 1 2 45 90 X Diuretics/furosemide
1ZD19 67 1 −9 26.0 −234 X X X ACe
1ZL06 79 1 −4 4.4 −17.6 X X no treatment
1Zd26 62 1 −3 19 −57 X X Diuretics/furosemide
1Zs19 66 1 −8 3.1 −24.8 X X no treatment
1ZT15 64 1 −8 11 −88 X X X no treatment
1ZA31 69 1 −6 3.0 −18.06 X X no treatment
1ZL01 89 1 −6 4.1 −24.6 X X X ACe, insulin nPh
1ZB08 76 1 −10 3.5 −35 X X ACe, diuretics
1ZC30 56 1 −8 3.5 −28 X X no treatment
1ZA10 52 1 −8 3.3 −26.4 X X simvastatin, omeprazole
1ZF06 84 1 −2 7.5 −15 X X ACe, ranitidine
1Zs04 80 1 −4 14 −56 X X Diuretics, ACe
1ZF03 57 1 −8 2.3 −18.4 X X Angiotensin ii antagonists,   
Crestor
1Zs02 62 1 −5 14.0 −70 X X X no treatment
1Zx17 68 1 −1 4.9 −4.9 X ACe, diuretics
1Zs28 76 1 −6 319 −1914 X X X Metformin ACe, 
Diuretics
1ZD22 74 1 −10 6.5 −65 X X X ACe, simvastatin
1ZR25 50 1 −2 5.26 −10.52 X X no treatment
1ZF28 71 1 −5 6.0 −30 X X X no treatment
1ZM11 59 1 −2 9 −18 X X Alpha blockers
1WR28 55 1 −5 4.2 −21 X X X ACe, selozok
Note: X = Right results in reference to the biopsies.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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of prostate carcinoma in pooled data from a recent meta-
analysis. Once regional lymph node involvement is present, 
the probability of death from prostate cancer is 70%, and 
50% of men with regional lymph node involvement will 
die in two years. Prostate cancer is a real risk for the aging 
man, because almost 10% of men older than 50 years are 
likely to develop clinically serious disease. Therefore, it 
should be detected at an early stage,16 and to improve early 
detection rates it is necessary to increase the sensitivity of 
the screening tests used.
In the current study, the sensitivities of PSA and digital 
rectal examination screening were 72.1% and 53.2%, 
respectively. Reducing the PSA cutoff point from 4 ng/mL 
to 3 ng/mL can increase the sensitivity, but doing so will 
reduce further the positive predictive value.16 It is also well 
known that PSA values for prostate cancer and benign 
prostate hyperplasia overlap considerably. Between 21% 
and 47% of men with histologically proven benign prostate 
hyperplasia have PSA levels .4 ng/mL, and up to 43% of 
men with prostate cancer will have a PSA level ,4 ng/mL. 
This overlap makes it harder to differentiate benign prostate 
hyperplasia from prostate carcinoma in the absence of a 
biopsy. PSA values also increase with age.17
With prostate cancer, the risk of overdiagnosis is likely 
to be much more relevant than with other types of cancer 
screening, because in men aged 55–60 years, the risk of 
death from other causes is considerably higher than that 
from prostate cancer. It is estimated that for every patient 
who dies of prostate cancer, at least 380 others have prostate 
cancer that cannot be detected clinically.18 The treatment of 
prostate cancer consists of radical surgery or radiotherapy, 
and both can cause complications, including a high frequency 
of sexual impotence, rectal and urinary dysfunction, as well 
and a mortality risk of 1%–2%.
Table 2 Analysis of the negative patients group
Patient  
code
Age Positive test = 1 
Negative test = 0
Delta  
DE
PSA All  
(DE-PSA)  
#-10.52
Delta  
DE #-5
PSA .4 All  
(DE-PSA)  
#-10.52
Correct treatment
1Ze22 55 0 −3 3.2 −9.6 X X X no treatment
1ZC01 57 0 1 3.3 3.3 X X X insulin, corticosteroid, ACe,   
Diuretics, metformin
1ZL10 73 0 −4 16 −64 X no treatment
1ZB11 65 0 0 2.6 0 X X X no treatment
1Zd08 64 0 6 4.9 29.4 X X no treatment
1ZD11 60 0 −6 4.4 −26.4 ACe, imipcamin, ranitidine
1Zd30 64 0 −4 4.7 −18.8 X no treatment
1ZC20 68 0 3 5.52 16.56 X X ACe
1ZP09 81 0 −6 5.61 −33.66 Angiotensin ii inhibitor, 
simvastatin
1ZL20 76 0 5 2.8 14 X X X ACe
1ZA04 62 0 −2 3.1 −6.2 X X X no treatment
1Zd18 63 0 −2 2.7 −5.4 X X X no treatment
1Zg21 67 0 0 3.2 0 X X X simvastatin, bromazepan
1ZB01 71 0 −4 4.7 −18.8 X Chondroitin
1ZA26 77 0 −5 7.0 −35 X X Cefalexin
1ZF11 69 0 −4 3.0 −12 X X X Digoxin, ACe
1ZA09 53 0 −10 4.2 −42 no treatment
1ZD11 54 0 −1 3.3 −3.3 X X X no treatment
iZdi8 68 0 −4 7.1 −28.4 X no treatment
1ZL11 73 0 −4 4 −16 X X ACe
1ZC11 69 0 3 5.7 17.1 X X no treatment
1Zg13 62 0 −2 3.1 −6.2 X X X no treatment
1Zi28 61 0 −2 2.9 −5.8 X X X Omeprazol
1ZD10 69 0 −4 23 −92 X ACe
1ZL14 62 0 2 10 20 X X Angiotensin ii inhibitor,  
Ranitidine
1ZM03 53 0 −3 2.8 −8.4 X X X Angiotensin ii inhibitor
1ZA31 49 0 −2 3.5 −7 X X X simvastatin, omeprazole
Note: X = Right results in reference to the biopsies.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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The EIS technique, when used as a screening test, 
meets the requirements of the World Health Organization 
guidelines stating that a screening test should be acceptable 
to the population, be rapidly performed (no more than two 
minutes), cost-effective and noninvasive, and that the total 
cost of finding a case should be economically balanced in 
relation to medical expenditure as a whole.
In the present study, the positive predictive values for 
PSA and digital rectal examination were about 25% and 
18%, respectively, which means one of four or five biopsies 
is unnecessary. Unnecessary biopsies can lead to multiple 
invasive procedures, anxiety for the patient, procedure-
related complications, and a high cost of health care delivery. 
To reduce further unnecessary procedures, a meta-analysis19 
has proposed use of transrectal ultrasonography in 
patients with elevated PSA levels but benign digital rectal 
examination findings, followed by biopsy only of visible 
abnormal lesions. If findings on digital rectal examination are 
abnormal, the patient should undergo transrectal ultrasound 
and then a biopsy, regardless of the PSA value. A small, 
organ-confined prostate tumor has an estimated doubling 
time of about four years. Thus, it will take about 15 years 
for a 1 mL tumor to become life-threatening. It would be 
more straightforward to say that until there is evidence for 
effectiveness of screening in decreasing mortality, based 
on these growth rates, a man would need to have at least 
15 years of remaining life expectancy to benefit from PSA   
screening.
In the US, there are 30.8 million men older than 50 years 
of age who qualify for PSA screening.20 According to our 
calculations, based on fees charged at one urologist’s office in 
New Jersey, the cost of PSA screening in all these men would 
be $3.1 billion. Of this population, 10.1% (approximately 
3.1 million men) will have PSA levels .4 ng/mL. Assuming 
all patients with abnormal PSA levels are referred to a 
urologist for further evaluation, the first visit will cost $275 
(for the office visit, urine analysis, and culture). The second 
visit will involve sonography of the prostate, bladder, pelvis, 
and renal organs, as well as guided needle biopsy, which 
can cost $2170 per patient. Therefore, the total cost of these 
two visits would exceed $7.6 billion for 3.1 million men. 
Of 3.1 million biopsies performed, 75%, ie, 2.3 million will 
be negative for prostate carcinoma.
In our study, the EIS delta parameter had a good 
specificity of 85.2% and a sensitivity of 65.2%, although we 
noted that for the eight positive patients, none of which were 
identified by the delta parameter, four are undergoing diuretic 
treatment and one is receiving an alpha-blocker treatment.
Conclusion
Using the EIS system as an independent predictor of 
prostate cancer, it has a good specificity of 85.2%.   However, 
the sensitivity of 62.5% will be a problem. Using the 
PSA reference of $4.1 ng/mL, adjunctive use of the EIS 
  system measuring bioimpedance and chronoamperometry 
could raise the sensitivity from 73.9% to 91.5% and the 
specificity from 51.9% to 59.3% in prostate cancer screening. 
To our knowledge, this is the first study using a noninvasive 
bioimpedance-chronoamperometry technique for prostate 
cancer screening. A longitudinal study is now under way to 
confirm our findings.
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